Cost-effectiveness analysis of SBRT versus IMRT: An emerging initial radiation treatment option for organ-confined prostate cancer

American Journal of Managed Care

Volumn 18, Issue 5, 2012, Pages

  Hodges, Joseph C ^a   Lotan, Yair ^a   Boike, Thomas P ^b   Benton, Rhonda ^a   Barrier, Alyson ^a   Timmerman, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Northern Michigan Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CASE REPORT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; UNITED STATES;

EID: 84864406548     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. American Cancer Society: Cancer facts and figures 2012. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2012
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103: 117-128, 2011
3. Ollendorf DA, Hayes J, McMahon P, et al: Management options for low-risk prostate cancer: A report on comparative effectiveness and value. Boston, MA, Institute for Clinical and Economic Review, 2009
4. Centers for Medicare & Medicaid Services, Medicare Evidence Development and Coverage Advisory Committee: Comparative evaluation of radiation treatments for clinically localized prostate cancer: An update. Centers for Medicare & Medicaid Services, Baltimore, MD, 2010
5. Centers for Medicare & Medicaid Services, Medicare Evidence Development and Coverage Advisory Committee: Outcomes of sipuleucel-T therapy. Centers for Medicare & Medicaid Services, Baltimore, MD, 2011
6. Leonhardt D: In health reform, a cancer offers an acid test. New York Times, July 8, 2009:A1
7. Hayes JH, Ollendorf DA, Pearson SD, et al: Active surveillance compared with initial treatment for men with low-risk prostate cancer: A decision analysis. JAMA 304:2373-2380, 2010
8. Nguyen PL, Gu X, Lipsitz SR, et al: Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517-1524, 2011
9. Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010
10. Rusthoven KE, Kavanagh BD, Burri SH, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579-1584, 2009
11. Schefter TE, Kavanagh BD, Timmerman RD, et al: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:1371-1378, 2005 (Pubitemid 40982057)
12. Fowler JR, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021-1031, 2001 (Pubitemid 32594841)
13. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101, 1999 (Pubitemid 29144800)
14. D'Souza WD, Thames HD: Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51:1-3, 2001 (Pubitemid 32758853)
15. Daçu A: Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 19:289-301, 2007
16. King CR, Brooks JD, Gill H, et al: Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73:1043-1048, 2009
17. Boike TP, Lotan Y, Cho LC, et al: Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020-2026, 2011
18. Zietman AL, Bae K, Slater JD, et al: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95- 09. J Clin Oncol 28:1106-1111, 2010
19. Zelefsky MJ, Fuks Z, Hunt M, et al: High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111-1116, 2002 (Pubitemid 34787844)
20. Storey MR, Pollack A, Zagars G, et al: Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48:635-642, 2000
21. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008 (Pubitemid 350251041)
22. Freeman DE, King CR: Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 6:3, 2011
23. Jabbari S, Weinberg VK, Kaprealian T, et al: Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 82:228-234, 2012
24. Konski A, Watkins-Bruner D, Feigenberg S, et al: Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 66:408-415, 2006 (Pubitemid 44332736)
25. King CR, Brooks JD, Gill H et al: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877-882, 2012
26. King C: Stereotactic body radiotherapy for prostate cancer: Current results of a phase II trial. Front Radiat Ther Oncol 43:428-437, 2011
27. Shipley WU, Lu JD, Pilepich MV, et al: Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54:1302-1310, 2002 (Pubitemid 35380028)
28. Beekman KW, Fleming MT, Scher HI, et al: Second-line chemotherapy for prostate cancer: Patient characteristics and survival. Clin Prostate Cancer 4:86-90, 2005 (Pubitemid 41474602)
29. Stewart ST, Lenert L, Bhatnagar V, et al: Utilities for prostate cancer health states in men aged 60 and older. Med Care 43:347-355, 2005 (Pubitemid 40515624)
30. Bayoumi AM, Brown AD, Garber AM: Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92:1731-1739, 2000
31. Albertsen PC, Aaronson NK, Muller MJ, et al: Health-related quality of life among patients with metastatic prostate cancer. Urology 49:207- 216; discussion 216-217
32. Piper NY, Kusada L, Lance R, et al: Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis 5:164-166, 2002 (Pubitemid 34777902)
33. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993 (Pubitemid 24013155)
34. Weinstein MC, Skinner JA: Comparative effectiveness and health care spending: Implications for reform. N Engl J Med 362:460-465, 2010
35. Social Security Administration: Actuarial life table 2010. http://www.ssa.gov/oact/NOTES/as120/LifeTables-Body.html
36. Miller DK, Homan SM: Determining transition probabilities: Confusion and suggestions. Med Decis Making 000000014:52-58, 1994 (Pubitemid 24032682)
37. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999 (Pubitemid 29211767)
38. Oefelein MG, Agarwal PK, Resnick MI: Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 171:1525-1528, 2004
39. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995- 2005, 2011
40. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
41. Konski A, Speier W, Hanlon A, et al: Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 25:3603-3608, 2007 (Pubitemid 47372597)
42. Gold MR, Siegel JE, Russell LB, et al (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996, 1-333
43. Meuning P: Cost-Effectiveness in Healthcare: A Practical Approach (ed 2). San Francisco, CA, Jossey-Bass, 2007
44. Fleming C, Wasson JH, Albertsen PE, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Outcomes Research Team. JAMA 269:2650-2658, 1993 (Pubitemid 23147702)